The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Injection Peptide Drug Market Research Report 2024

Global Injection Peptide Drug Market Research Report 2024

Publishing Date : Oct, 2023

License Type :
 

Report Code : 1689056

No of Pages : 93

Synopsis
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less.
Global Injection Peptide Drug market is projected to reach US$ 62200 million in 2029, increasing from US$ 35410 million in 2022, with the CAGR of 9.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Injection Peptide Drug market research.
The Peptide Drug market is driven by the increasing recognition of peptides as a versatile and promising class of therapeutics. Peptides offer the potential to target specific biological pathways and cellular functions with high specificity, making them valuable candidates for treating a wide range of diseases, including cancer, metabolic disorders, and cardiovascular conditions. The growing understanding of peptide structure-activity relationships, coupled with advancements in peptide synthesis and modification techniques, contribute to the development of more stable and bioavailable peptide drugs, fostering market growth. Moreover, the rise in personalized medicine approaches and the need for more targeted therapies align with the development of peptide-based treatments that can be tailored to individual patient profiles. However, the market also faces challenges, including optimizing peptide delivery systems, enhancing bioavailability, and addressing potential immunogenicity and stability issues. Additionally, the complexity of peptide synthesis, the need for stringent regulatory approvals, and the competition from other therapeutic modalities pose obstacles for manufacturers and researchers. To succeed, stakeholders must focus on innovative peptide design, efficient synthesis methods, and comprehensive pre-clinical and clinical studies to demonstrate the safety and efficacy of peptide drugs. Addressing challenges while harnessing the therapeutic potential of peptides will be essential for driving the growth and adoption of peptide-based treatments in various medical applications.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Injection Peptide Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Segment by Type
Intravenous Injection
Subcutaneous Injection
Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Injection Peptide Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Injection Peptide Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Intravenous Injection
1.2.3 Subcutaneous Injection
1.3 Market by Application
1.3.1 Global Injection Peptide Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Central Nervous System
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Injection Peptide Drug Market Perspective (2018-2029)
2.2 Injection Peptide Drug Growth Trends by Region
2.2.1 Global Injection Peptide Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Injection Peptide Drug Historic Market Size by Region (2018-2023)
2.2.3 Injection Peptide Drug Forecasted Market Size by Region (2024-2029)
2.3 Injection Peptide Drug Market Dynamics
2.3.1 Injection Peptide Drug Industry Trends
2.3.2 Injection Peptide Drug Market Drivers
2.3.3 Injection Peptide Drug Market Challenges
2.3.4 Injection Peptide Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Injection Peptide Drug Players by Revenue
3.1.1 Global Top Injection Peptide Drug Players by Revenue (2018-2023)
3.1.2 Global Injection Peptide Drug Revenue Market Share by Players (2018-2023)
3.2 Global Injection Peptide Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Injection Peptide Drug Revenue
3.4 Global Injection Peptide Drug Market Concentration Ratio
3.4.1 Global Injection Peptide Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Injection Peptide Drug Revenue in 2022
3.5 Injection Peptide Drug Key Players Head office and Area Served
3.6 Key Players Injection Peptide Drug Product Solution and Service
3.7 Date of Enter into Injection Peptide Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Injection Peptide Drug Breakdown Data by Type
4.1 Global Injection Peptide Drug Historic Market Size by Type (2018-2023)
4.2 Global Injection Peptide Drug Forecasted Market Size by Type (2024-2029)
5 Injection Peptide Drug Breakdown Data by Application
5.1 Global Injection Peptide Drug Historic Market Size by Application (2018-2023)
5.2 Global Injection Peptide Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Injection Peptide Drug Market Size (2018-2029)
6.2 North America Injection Peptide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Injection Peptide Drug Market Size by Country (2018-2023)
6.4 North America Injection Peptide Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Injection Peptide Drug Market Size (2018-2029)
7.2 Europe Injection Peptide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Injection Peptide Drug Market Size by Country (2018-2023)
7.4 Europe Injection Peptide Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Injection Peptide Drug Market Size (2018-2029)
8.2 Asia-Pacific Injection Peptide Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Injection Peptide Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Injection Peptide Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Injection Peptide Drug Market Size (2018-2029)
9.2 Latin America Injection Peptide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Injection Peptide Drug Market Size by Country (2018-2023)
9.4 Latin America Injection Peptide Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Injection Peptide Drug Market Size (2018-2029)
10.2 Middle East & Africa Injection Peptide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Injection Peptide Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Injection Peptide Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Injection Peptide Drug Introduction
11.1.4 Sanofi Revenue in Injection Peptide Drug Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Injection Peptide Drug Introduction
11.2.4 Teva Revenue in Injection Peptide Drug Business (2018-2023)
11.2.5 Teva Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Detail
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Injection Peptide Drug Introduction
11.3.4 Novo Nordisk Revenue in Injection Peptide Drug Business (2018-2023)
11.3.5 Novo Nordisk Recent Development
11.4 Takeda
11.4.1 Takeda Company Detail
11.4.2 Takeda Business Overview
11.4.3 Takeda Injection Peptide Drug Introduction
11.4.4 Takeda Revenue in Injection Peptide Drug Business (2018-2023)
11.4.5 Takeda Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Detail
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Injection Peptide Drug Introduction
11.5.4 Eli Lilly Revenue in Injection Peptide Drug Business (2018-2023)
11.5.5 Eli Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Injection Peptide Drug Introduction
11.6.4 AstraZeneca Revenue in Injection Peptide Drug Business (2018-2023)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Injection Peptide Drug Introduction
11.7.4 Novartis Revenue in Injection Peptide Drug Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Detail
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Injection Peptide Drug Introduction
11.8.4 AbbVie Revenue in Injection Peptide Drug Business (2018-2023)
11.8.5 AbbVie Recent Development
11.9 Ipsen
11.9.1 Ipsen Company Detail
11.9.2 Ipsen Business Overview
11.9.3 Ipsen Injection Peptide Drug Introduction
11.9.4 Ipsen Revenue in Injection Peptide Drug Business (2018-2023)
11.9.5 Ipsen Recent Development
11.10 Ferring
11.10.1 Ferring Company Detail
11.10.2 Ferring Business Overview
11.10.3 Ferring Injection Peptide Drug Introduction
11.10.4 Ferring Revenue in Injection Peptide Drug Business (2018-2023)
11.10.5 Ferring Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Injection Peptide Drug Introduction
11.11.4 Merck Revenue in Injection Peptide Drug Business (2018-2023)
11.11.5 Merck Recent Development
11.12 The Medicines
11.12.1 The Medicines Company Detail
11.12.2 The Medicines Business Overview
11.12.3 The Medicines Injection Peptide Drug Introduction
11.12.4 The Medicines Revenue in Injection Peptide Drug Business (2018-2023)
11.12.5 The Medicines Recent Development
11.13 J & J
11.13.1 J & J Company Detail
11.13.2 J & J Business Overview
11.13.3 J & J Injection Peptide Drug Introduction
11.13.4 J & J Revenue in Injection Peptide Drug Business (2018-2023)
11.13.5 J & J Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’